Matinas BioPharma Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

A reconciliation of the statutory U.S. federal rate to the Company's effective tax rate is as follows:

	Years ended
	December 31,
	2014			2013
Percent of pre-tax income:
U.S. federal statutory income tax rate		34.0	%		34.0	%
State taxes, net of federal benefit		0.1	%		-	%
Permanent items		(3.1)	%		(1.4)	%
Research and development credit		0.9	%		0.4	%
Change in valuation allowance		(31.9)	%		(33.0)	%

Effective income tax rate		0.0	%		0.0	%

Significant components of the Company's deferred tax assets (liabilities) for 2014 and 2013 consist of the following:

	As of December 31,
	2014		2013
Deferred tax assets (liabilities)
Share-based compensation	$	489,017	$	28,158
Intangible assets		88,764		9,103
Warrants		43,997		42,934
Accrued liability		-		60,048
Net operating loss carryforwards		4,379,541		1,318,000
Federal research and development credit carryforwards		241,318		24,425
Depreciation		(14,870)		-
Deferred income tax assets		5,227,767		1,482,668
Valuation allowance		(5,227,767)		(1,482,668)
Net deferred tax assets	$	0	$	0